Third quarter 2017, compared to 2016, Group
» 50% growth in orders for Episealer® knee implants during the quarter with 42 (28) approved orders. Invoicing taking place at delivery during both Q3 and Q4 2017
» Group net sales increased by 1% to SEK 520,284 (516,641)
» Other operating income amounted to SEK 97,716 (–)
» Loss before tax amounted to SEK –13,518,593 (–15,042,517)
» Earnings per share (weighted average) amounted to SEK –0.45 (–0.79)
Significant events during the third quarter
» 100 patient multi-center study of the Episealer® knee implant fully recruited
» Episurf Medical’s 100th Episealer® Femoral Twin implant demonstrates rapid clinical adoption
» Episurf Medical’s 50th Episealer® implant in Belgium
» Episurf Medical reached milestone of 250 implants sold
» Episurf Medical reported a brief clinical update
» Management group changes in Episurf Medical were announced
» Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independent hospital providers
» Case-report with clinical data of Episealer® patient was published
» Another preclinical paper on the Episealer® Implant published
» Dennis D. Stripe re-assumed the position as non-executive chairman of the board
Significant events after the third quarter
» Episurf Medical obtained another new patent in China
» Fredrik Zetterberg appointed Head of Marketing for Episurf Medical
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 10 November 2018.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlContact:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlTitle:protected] => <h1 style="font-family: arial,helvetica,sans-serif;">INTERIM REPORT 1 JULY – 30 SEPTEMBER 2017</h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[Body:protected] => Third quarter 2017, compared to 2016, Group
» 50% growth in orders for Episealer® knee implants during the quarter with 42 (28) approved orders. Invoicing taking place at delivery during both Q3 and Q4 2017
» Group net sales increased by 1% to SEK 520,284 (516,641)
» Other operating income amounted to SEK 97,716 (–)
» Loss before tax amounted to SEK –13,518,593 (–15,042,517)
» Earnings per share (weighted average) amounted to SEK –0.45 (–0.79)
Significant events during the third quarter
» 100 patient multi-center study of the Episealer® knee implant fully recruited
» Episurf Medical’s 100th Episealer® Femoral Twin implant demonstrates rapid clinical adoption
» Episurf Medical’s 50th Episealer® implant in Belgium
» Episurf Medical reached milestone of 250 implants sold
» Episurf Medical reported a brief clinical update
» Management group changes in Episurf Medical were announced
» Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independent hospital providers
» Case-report with clinical data of Episealer® patient was published
» Another preclinical paper on the Episealer® Implant published
» Dennis D. Stripe re-assumed the position as non-executive chairman of the board
Significant events after the third quarter
» Episurf Medical obtained another new patent in China
» Fredrik Zetterberg appointed Head of Marketing for Episurf Medical
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 10 November 2018.
[HtmlBody:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>Third quarter 2017, compared to 2016, Group</strong> <br />» 50% growth in orders for Episealer® knee implants during the quarter with 42 (28) approved orders. Invoicing taking place at delivery during both Q3 and Q4 2017 <br />» Group net sales increased by 1% to SEK 520,284 (516,641) <br />» Other operating income amounted to SEK 97,716 (–) <br />» Loss before tax amounted to SEK –13,518,593 (–15,042,517) <br />» Earnings per share (weighted average) amounted to SEK –0.45 (–0.79) </span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>Significant events during the third quarter</strong> <br />» 100 patient multi-center study of the Episealer® knee implant fully recruited <br />» Episurf Medical’s 100th Episealer® Femoral Twin implant demonstrates rapid clinical adoption <br />» Episurf Medical’s 50th Episealer® implant in Belgium <br />» Episurf Medical reached milestone of 250 implants sold <br />» Episurf Medical reported a brief clinical update <br />» Management group changes in Episurf Medical were announced <br />» Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independent hospital providers <br />» Case-report with clinical data of Episealer® patient was published <br />» Another preclinical paper on the Episealer® Implant published <br />» Dennis D. Stripe re-assumed the position as non-executive chairman of the board</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>Significant events after the third quarter</strong> <br />» Episurf Medical obtained another new patent in China <br />» Fredrik Zetterberg appointed Head of Marketing for Episurf Medical</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong><br /></strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>For more information, please contact:</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Email: <a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong><br /></strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>About Episurf Medical</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 10 November 2018.</em></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => R3
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 153
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 9309
)
[4] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/2387457/749315.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => INTERIM REPORT 1 JULY – 30 SEPTEMBER 2017
[Description:protected] => INTERIM REPORT 1 JULY – 30 SEPTEMBER 2017
[CreateDate:protected] => 2017-11-10T07:30:18Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 2726882
[EncryptedId:protected] => 77E1D0FA4ECF6166
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2017-11-10T07:30:00Z
[LastChangeDate:protected] => 2017-11-10T07:30:18Z
[Title:protected] => INTERIM REPORT 1 JULY – 30 SEPTEMBER 2017
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => RPT
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/interim-report-1-july---30-september-2017,c2387457
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)